Get the Stockscreener App
264.22
1.11%
-2.96
After Hours:
263.01
-1.21
-0.46%
Natera Inc stock is traded at $264.22, with a volume of 806.49K.
It is down -1.11% in the last 24 hours and up +15.48% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$267.18
Open:
$263.375
24h Volume:
806.49K
Relative Volume:
0.54
Market Cap:
$37.84B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-160.99
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
-4.74%
1M Performance:
+15.48%
6M Performance:
+8.77%
1Y Performance:
+88.84%
1-Day Range:
$257.84
$266.00
1-Week Range:
$255.66
$282.00
52-Week Range:
$131.81
$288.04
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
264.22 | 38.26B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
526.46 | 194.53B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
179.14 | 125.84B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
545.00 | 43.58B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
133.46 | 37.52B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera (NTRA) Reveals Promising Advances in Merkel Cell Carcinom - GuruFocus
Natera’s Signatera test outperforms standard MCC monitoring tool - Investing.com
What's Driving Natera's Recent Stock Action - Kavout | AI
Form 4 Natera Inc For: 21 July By Investing.com - Investing.com South Africa
Natera co-founder Sheena sells $410,825 of company stock By Investing.com - Investing.com South Africa
Natera director Rowan Chapman sells $37,100 in shares - Investing.com UK
Natera director Rowan Chapman sells $37,100 in shares By Investing.com - Investing.com South Africa
Natera co-founder Sheena sells $410,825 of company stock - Investing.com
Natera stock trades steady as genetic testing growth supports recent earnings - Ad-hoc-news.de
(NTRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Natera Inc. (NTRA) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Natera Inc. (NTRA) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Natera Inc. (NTRA) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued - simplywall.st
Natera co-founder, Director Sheena Jonathan disposes of 1,500 common shares worth $410,322.91 - Bitget
Natera director Rowan Chapman sells $37,100 in company stock - Investing.com UK
Insider Sell: Rowan Chapman Sells Shares of Natera Inc (NTRA) - GuruFocus
Natera co-founder Sheena Jonathan sells $410,825 in NTRA stock - Investing.com UK
Natera director Rowan Chapman sells $37,100 in company stock By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 17 July By Investing.com - Investing.com South Africa
Natera (NASDAQ: NTRA) co-founder’s trusts sell 1,500 shares - Stock Titan
Natera (NASDAQ: NTRA) director Chapman sells 135 shares in 10b5-1 trade - Stock Titan
Natera co-founder Sheena Jonathan sells $410,825 in NTRA stock By Investing.com - Investing.com Canada
Druckenmiller’s top holding shifts to Natera - msn.com
The Bull Case For Natera (NTRA) Could Change Following New Signatera JAMA Oncology Evidence On MRD-Guided Chemotherapy - simplywall.st
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio - Business Wire
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks - Yahoo Finance
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves. - The Motley Fool
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling - Kavout | AI
Natera co-founder Sheena Jonathan sells $836,898 in stock - Investing.com UK
Natera co-founder Sheena Jonathan sells $836,898 in stock By Investing.com - Investing.com India
Form 4 Natera Inc For: 15 July By Investing.com - Investing.com Nigeria
Natera (NTRA) co-founder sells 3,150 shares under Rule 10b5-1 plan - Stock Titan
Rowan Emma Chapman (NASDAQ: NTRA) files Form 144 to sell shares - Stock Titan
Form 144 Natera For: 15 July By Investing.com - Investing.com Canada
NTRA (NASDAQ: NTRA) holder plans sale of 1,500 common shares - Stock Titan
NATERA INC : TD COWEN RAISES TARGET PRICE TO $325 FROM $280 - Moomoo
NTRA Maintained by Canaccord Genuity -- Price Target Raised to $330 - GuruFocus
Enterprise value to EBITDA forward of Natera, Inc. – BX:NTRA - TradingView
Form 144 Natera For: 13 July By Investing.com - Investing.com Nigeria
NTRA (NASDAQ: NTRA) plans $2.5M sale after April–June share sales - Stock Titan
Enterprise value to EBITDA forward of Natera, Inc. – XETR:45E - TradingView
Did EU Class C Status for Signatera Reshape Natera’s (NTRA) Long-Term Diagnostics Strategy? - Yahoo Finance
What's Driving Natera's Recent Stock Action and Insider Selling - Kavout | AI
Is Natera (NTRA) Fully Valued As Signatera Wins EU IVDR Certification? - simplywall.st
Natera (NTRA) Secures EU Certification, Is The Upside Already Priced In? - Yahoo Finance
Why Natera (NTRA) Stock Is Down Today - Quiver Quantitative
Natera (NTRA) Signatera Data Shows Who Benefits From Chemotherapy After CRC Surgery - Yahoo Finance
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers - Yahoo Finance
Natera (NTRA) Stock Still Looks Expensive After A Very Large Run - Yahoo Finance
NTRA Maintained by Morgan Stanley -- Price Target Raised to $310 - GuruFocus
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chapman Rowan E | Director |
Jul 15 '26 |
Sale |
274.82 |
135 |
37,101 |
4,663 |
| Sheena Jonathan | CO-FOUNDER |
Jul 13 '26 |
Sale |
265.68 |
3,150 |
836,898 |
246,202 |
0.45%
1.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):